As teze­pelum­ab awaits FDA de­ci­sion, Am­gen and As­traZeneca tout more da­ta from the Phase III study

As As­traZeneca and Am­gen’s Dupix­ent chal­lenger awaits a de­ci­sion by the FDA, the com­pa­nies are tout­ing new da­ta they hope could bol­ster their case.

Re­searchers re­vealed ad­di­tion­al re­sults from a piv­otal Phase III tri­al for As­traZeneca and Am­gen’s teze­pelum­ab over the week­end, study­ing the treat­ment in se­vere, un­con­trolled asth­ma. In an ex­plorato­ry analy­sis look­ing at pa­tients with or with­out re­port­ed nasal polyps, teze­pelum­ab showed it can re­duce asth­ma ex­ac­er­ba­tion by 86% in the for­mer group and 52% in the lat­ter when com­pared to stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER